Enlivex Therapeutics Ltd.
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Enlivex Therapeutics Ltd. is a clinical-stage biopharmaceutical company developing macrophage reprogramming immunotherapies. Its lead product candidate, Allocetra™, is a universal, off-the-shelf cell therapy platform designed to restore immune system balance. The company is evaluating Allocetra™ in clinical trials for the treatment of a range of indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The therapy is designed for flexible administration and has demonstrated a favorable safety profile in patients.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Enlivex Therapeutics Ltd. and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-11 17:22 |
Foreign Filer Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following…
|
English | 194.2 KB | |
| 2025-09-11 17:22 |
Foreign Filer Report
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following…
|
English | 36.3 KB | |
| 2025-09-09 17:16 |
Foreign Filer Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Alloce…
|
English | 228.7 KB | |
| 2025-09-09 17:16 |
Foreign Filer Report
Enlivex Announces Issuance of New Patent Application Covering the Use of Alloce…
|
English | 36.3 KB | |
| 2025-08-18 17:12 |
Foreign Filer Report
Presentation- PHASE IIA TOPLINE RESULTS
|
English | 3.8 MB | |
| 2025-08-18 17:12 |
Foreign Filer Report
Presentation- PHASE IIA TOPLINE RESULTS
|
English | 36.4 KB | |
| 2025-08-18 16:59 |
Foreign Filer Report
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Pha…
|
English | 156.5 KB | |
| 2025-08-18 16:59 |
Foreign Filer Report
Form 6-K- Positive Topline Data From Multi-Country, Randomized, Controlled, Pha…
|
English | 36.4 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 173.8 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 36.3 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 149.8 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 36.3 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 271.6 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 36.5 KB | |
| 2025-05-14 01:32 |
Prospectus
Renewal of ATM plan
|
English | 545.8 KB |
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
